NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024
A scientist in a lab researching the biology of a cancer cell.
The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC's target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy.
According to NextCure, Inc. (NASDAQ:NXTC)'s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the 'Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology' session.
NXTC closed nearly 6% higher on May 29.
While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this
READ NEXT: and
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Safety Shot Acquires 10% Revenue Sharing Interest in Revenue Generating BONK.fun and Appoints BONK Founding Core Members to Board
SCOTTSDALE, AZ , Aug. 12, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) today announced it has acquired a 10% revenue sharing interest in the profitable launchpad, This valuable revenue sharing interest, along with an initial $25 million in BONK tokens, was the primary consideration for the preferred stock transaction announced yesterday. In a landmark move that signals a full alignment of interests, members of the BONK founding core group, including Mitchell Rudy (AKA Nom), will be appointed to the Safety Shot Board of Directors, constituting 50% of the board seats. Further solidifying its commitment to this new direction, Safety Shot also announced it has reserved the ticker symbol 'BNKK' with Nasdaq. is a decentralized platform on the Solana blockchain that allows anyone to instantly create and launch new meme coins without needing any coding expertise. It has experienced explosive growth since its launch in April 2025, rapidly becoming a dominant player in its sector. The platform is deeply integrated with the BONK ecosystem. A portion of the revenue it generates is used to buy back and burn BONK tokens on the open market. This creates constant buying pressure and reduces the supply of BONK, which is designed to increase its value and strengthen the entire ecosystem, which in turn drives more activity back to the platform. "We've built one of the most powerful, decentralized ecosystems from the ground up. Since our launch on Christmas day 2022, BONK's growth has been explosive. We have surged to a market capitalization of over $2 billion. By integrating with Safety Shot, Inc., we are creating a first-of-its-kind bridge for public market investors to directly participate in the revenue and growth of one of the most active communities in DeFi. Integrating revenue with Safety Shot will be the next step of empowering the token flywheel of BONK. This is the future of how digital assets and traditional finance will merge, and we're thrilled to build that future here', says Mitchell Rudy, one the founding core contributors of BONK.' Unlike other crypto strategies that have been announced, is different in the fact that investors will be participating in revenues generated by the platform rather than earning fees from staking. Rudy says, 'Staking offers a relatively stable, but limited, yield that is always at the mercy of the underlying token's price. The revenue share offers uncapped, exponential growth potential tied to the success of a market-leading business. It's a bet on the growth of an entire sector, not just a single asset. For Safety Shot investors, this means the Company's value is being tied to a real, high-margin, cash flow stream, which is a much more powerful and exciting proposition than simply holding tokens and hoping they go up.' In July 2025 alone, generated over $35 million in user fees. This level of profitability places it among the top 10 most profitable decentralized applications in the entire world, alongside major crypto exchanges and lending protocols, according to data from analytics platform DefiLlama. Safety Shot will reinvest approximately 90% of its revenue income from into a treasury of BONK tokens, creating a powerful growth model for the Company. BONK has solidified its position as a top meme coin globally and the mascot of the Solana blockchain. As a decentralized digital platform, operating costs are incredibly low relative to its revenue. This means as revenue grows the vast majority of that revenue can flow directly to profit, which will then be used to buy BONK tokens and add them to the treasury. The platform's activity has been immense. On peak days, it has facilitated the launch of over 20,000 new tokens in a single 24-hour period. This massive volume of new projects drives significant economic activity, with daily trading volume on the platform has exceeded $100 million. 'Today's announcements represent the next logical step in our corporate evolution,' said Jarrett Boon, CEO of Safety Shot. 'Acquiring a direct revenue stream from welcoming the visionary BONK founding core team to our board, and reserving the 'BNKK' ticker symbol are clear and deliberate actions. This strategy goes far beyond simply holding tokens; we are deeply integrating our public company with a proven, revenue-generating leader in the digital asset space. We are confident this model will unlock significant long-term value for our shareholders, following a successful blueprint that has been well-received by the market.' The constant creation of new meme coins on Solana is like a modern-day gold rush. profits by selling 'picks and shovels" to every token creator. It takes a fee from the volume of activity. Dominari Securities, LLC. is serving as the exclusive financial advisor to Safety Shot in connection with the transaction. About Safety Shot, Inc.: Safety Shot, Inc. (Nasdaq: SHOT) is a company evolving to bridge the gap between traditional public markets and the digital asset ecosystem. Following its strategic integration with the Company is executing a new strategy focused on acquiring revenue-generating assets within the DeFi space to build a robust treasury of digital assets. The Company's beverage division holds the patented Safety Shot beverage, designed to rapidly reduce blood alcohol content as well as Yerbaé's plant-based, energy beverage. About is a decentralized platform on the Solana blockchain that allows anyone to instantly create and launch new meme coins without needing any coding expertise. It has experienced explosive growth since its launch in April 2025, rapidly becoming a dominant player in its sector. Investor Relations: Phone: 561-244-7100 Email: investors@ Forward-Looking Statements: This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the expected completion of the acquisition. These forward-looking statements are based on the current expectations of the management of Safety Shot and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Safety Shot, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Such statements are subject to risks and uncertainties, and actual results could differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the performance of BONK tokens, the successful alliance and operational success with the ability to execute on the Company's treasury strategy, and other risks detailed in Safety Shot's filings with the Securities and Exchange Commission.
Yahoo
11 minutes ago
- Yahoo
Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings
Cytokinetics Incorporated (NASDAQ:CYTK) is one of the best upside stocks to invest in now. On August 8, Citi lowered the firm's price target on Cytokinetics to $77 from $80, while keeping a Buy rating on the shares. This sentiment followed the company's Q2 2025 earnings report, which the firm views as uneventful. In Q2, Cytokinetics reported a net loss of $134.4 million, or $1.12 per share, which was an improvement from the net loss of $143.3 million, or $1.31 per share, reported in Q2 2024. Cytokinetics ended the quarter with ~$1.04 billion in cash and investments, which was a decrease from the $1.09 billion reported at the end of Q1 2025. A lab technician using a microscope to examine the biopharmaceutical company's molecules. In terms of clinical development, the FDA extended the PDUFA date for Aficamten to December 26, which may delay the drug's approval and launch timeline. However, the company noted that all Good Clinical Practice/GCP inspections for Aficamten were completed with no negative observations, which is a positive sign for the regulatory process. The company is preparing for a late-cycle meeting with the FDA in September, which is scheduled to align with the PDUFA date extension. Cytokinetics Incorporated (NASDAQ:CYTK) is a late-stage biopharmaceutical company that discovers, develops, and commercializes muscle activators and inhibitors as potential treatments for debilitating diseases in the US. While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
20 minutes ago
- Business Insider
M&A News: UnitedHealth (UNH) Closes $3.3B Amedisys Deal After Two-Year Antitrust Battle
Health insurer UnitedHealth (UNH) has finally completed its $3.3 billion acquisition of Amedisys, a home health and hospice provider, after two years of regulatory hurdles due to antitrust concerns. The deal, executed through UNH's Optum division, marks a major expansion of its footprint in home-based care. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Upon closing, Amedisys repaid $399.2 million to clear all outstanding debt. With the merger complete, Amedisys stock will no longer be traded on the Nasdaq. Each share of Amedisys common stock was converted into $101 in cash for shareholders. Regulatory Roadblocks and DOJ Settlement The merger faced intense scrutiny from the DOJ, which sued to block the deal in November 2024. Regulators feared the combination of Amedisys and UnitedHealth would stifle competition in home health and hospice markets. To resolve these issues, the companies entered a settlement with the DOJ. They have agreed to divest 164 facilities across 19 states to BrightSpring Health Services and The Pennant Group (PNTG). Further, Amedisys paid a $1.1 million civil penalty for false certification and agreed to antitrust compliance training. With Amedisys now part of UnitedHealth, the combined company is the largest hospice provider in the U.S., caring for over 465,000 patients a year. The deal supports Optum's plan to offer more connected and affordable care at home. Is UNH a Good Buy Right Now? Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, four Holds, and two Sells assigned in the last three months. At $312.65, the average UnitedHealth stock price target implies a 15.48% upside potential.
